AESKUCARE
DEAD

Serial Number

88066252

Owner

Aeneas GmbH & Co. KG

Attorney

Ralph G. Fischer

Filing Date

Aug 6, 2018

Add to watchlist:

No watchlists yet
View on USPTO

AESKUCARE Trademark

Serial Number: 88066252

AESKUCARE is a trademark filed by Aeneas GmbH & Co. KG on August 6, 2018. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Aeneas GmbH & Co. KG (12 trademarks)

Mikroforum Ring 2
Wendelsheim 55234 , DE

Entity Type: 03

Trademark Details

Filing Date

August 6, 2018

Registration Date

Not Registered

Goods & Services

Diagnostic preparations for clinical or medical laboratory use; Diagnostic reagents for clinical use; Diagnostic reagents for in-vitro clinical laboratory use

Medical, chemical and biological test kits, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing for medical purposes, and test reagents, namely, genetic identity tests comprised of reagents for medical purposes; Antiserums for diagnostic purposes; Chemical reagents for medical diagnostic, medical or veterinary purposes; Medical or veterinary chemical test reagents for medical use; Chemical test reagents for medical use; Diagnostic preparations for medical or veterinary purposes; Diagnostic preparations for medical and veterinary purposes; Diagnostic preparations for medical, pharmaceutical or veterinary purposes; Diagnostic biomarker reagents for medical purposes; Diagnostic testing materials for medical use, namely, medical diagnosis test strips for blood analysis or bodily fluids analysis; Diagnostic reagents for medical use; Diagnostic substances for medical use; Immunoassay reagents for medical or medical diagnostic purposes; In vitro diagnostic preparations for medical use; Indicators for medical diagnosis, namely, diagnostic preparations for medical purposes; Medical diagnostic test strips for blood analysis or bodily fluids analysis; Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents; Preparations of microorganisms for medical or veterinary use; Preparations for detecting genetic predispositions for medical purposes; Preparations for detecting mutation in prion genes for medical purposes; Chemical reagents for use in analysis for veterinary purposes; Chemical reagents for analysis purposes for medical diagnostic, medical or veterinary purposes; Reagents for use in diagnostic tests comprised of veterinary diagnostic reagents; Diagnostic reagents for in-vitro laboratory use for medical purposes; Diagnostic reagents for in-vitro laboratory use for veterinary purposes; Diagnostic reagents for blood grouping for medical purposes; Medical diagnostic reagents for use with testing apparatus for testing of blood analysis or bodily fluids analysis for autoimmune diseases, neurological diseases or cancer for medical or medical diagnostic purposes; Diagnostic reagents for use in diagnostic tests and analyses for testing and analysis of blood or bodily fluids for autoimmune diseases, neurological diseases or cancer for medical purposes; Diagnostic reagents for use with testing apparatus for testing of blood or bodily fluids for autoimmune diseases, neurological diseases or cancer for medical diagnostic or veterinary purposes; Reactants for medical or veterinary diagnosis, namely, diagnostic reagents for medical and veterinary uses; Veterinary diagnostic reagents; Clinical medical reagents; Biological reagents for medical, medical diagnostic and veterinary purposes; Chemical reagents for medical, medical diagnostic and veterinary purposes; Chemical reagents for medical and veterinary purposes; Reagents for microbiological analysis, for medical or veterinary purposes; Genetic identity tests, consisting of reagents for medical purposes; Reagents and media for medical and veterinary diagnostic purposes; Reagents for medical use; Reagents for medical and veterinary genetic testing; Chemical preparations for use in DNA analysis for medical use; Chemical preparations for medical and medical diagnostic purposes, namely, for autoimmune diseases, neurological diseases or cancer; Blood for medical purposes, and blood plasma for medical diagnostic purposes; Biological preparations for medical, medical diagnostic and veterinary purposes for the treatment of autoimmune diseases, neurological diseases or cancer; Mixed biological preparations for medical and medical diagnostic purposes for the prevention and treatment of infectious diseases; Blood plasma; Blood components, namely, platelet rich blood plasma and stem cells for medical use; Blood protein fractions, namely, blood plasma fractions or bodily fluid fractions for medical diagnostic purposes and medical therapeutic purposes; Enzymes for medical, medical diagnostic and veterinary purposes; Enzyme preparations for medical and veterinary purposes; By-products of the processing of cereals for medical and medical diagnostic purposes; Nucleic acid sequences for medical diagnostic, medical and veterinary purposes

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Feb 2, 2026 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Feb 2, 2026 ABN2
ASSIGNED TO EXAMINER
Dec 8, 2025 DOCK
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Sep 15, 2025 GNS2
INQUIRY TO SUSPENSION E-MAILED
Sep 15, 2025 GNSI
SUSPENSION INQUIRY WRITTEN
Sep 15, 2025 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Aug 8, 2025 RCCK
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jun 17, 2025 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 17, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 17, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 17, 2025 REAP
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Feb 6, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Feb 6, 2025 GNSL
SUSPENSION LETTER WRITTEN
Feb 6, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 6, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 6, 2025 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Feb 5, 2025 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jan 22, 2025 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jan 22, 2025 GNSI
SUSPENSION INQUIRY WRITTEN
Jan 22, 2025 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jun 17, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Jun 17, 2024 GNSL
SUSPENSION LETTER WRITTEN
Jun 17, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 17, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 17, 2024 CRFA
ASSIGNED TO LIE
Jun 17, 2024 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Feb 19, 2024 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Nov 20, 2023 GNS2
INQUIRY TO SUSPENSION E-MAILED
Nov 20, 2023 GNSI
SUSPENSION INQUIRY WRITTEN
Nov 20, 2023 CNSI
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
May 22, 2023 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Nov 21, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
Nov 21, 2022 GNSL
SUSPENSION LETTER WRITTEN
Nov 21, 2022 CNSL
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
May 24, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
May 24, 2022 GNSL
SUSPENSION LETTER WRITTEN
May 24, 2022 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
May 24, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 24, 2022 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 11, 2022 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Nov 16, 2021 GNS2
INQUIRY TO SUSPENSION E-MAILED
Nov 16, 2021 GNSI
SUSPENSION INQUIRY WRITTEN
Nov 16, 2021 CNSI
ASSIGNED TO EXAMINER
Nov 15, 2021 DOCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Nov 8, 2021 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
May 5, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
May 5, 2021 GNSL
SUSPENSION LETTER WRITTEN
May 5, 2021 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
May 5, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 5, 2021 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Apr 22, 2021 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Nov 24, 2020 GNS2
INQUIRY TO SUSPENSION E-MAILED
Nov 24, 2020 GNSI
SUSPENSION INQUIRY WRITTEN
Nov 24, 2020 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Nov 10, 2020 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 10, 2020 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 10, 2020 GNSL
SUSPENSION LETTER WRITTEN
Apr 10, 2020 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 7, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 7, 2020 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Apr 2, 2020 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Oct 9, 2019 GNS2
INQUIRY TO SUSPENSION E-MAILED
Oct 9, 2019 GNSI
SUSPENSION INQUIRY WRITTEN
Oct 9, 2019 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Oct 9, 2019 RCCK
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 7, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 7, 2019 REAP
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 30, 2019 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 30, 2019 GNSL
SUSPENSION LETTER WRITTEN
Mar 30, 2019 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 13, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 13, 2019 CRFA
ASSIGNED TO LIE
Mar 11, 2019 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 8, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 13, 2018 GNRN
NON-FINAL ACTION E-MAILED
Sep 13, 2018 GNRT
NON-FINAL ACTION WRITTEN
Sep 13, 2018 CNRT
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 12, 2018 GNRN
NON-FINAL ACTION E-MAILED
Sep 12, 2018 GNRT
NON-FINAL ACTION WRITTEN
Sep 12, 2018 CNRT
ASSIGNED TO EXAMINER
Sep 11, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 10, 2018 NWOS
NEW APPLICATION ENTERED
Aug 9, 2018 NWAP